注射用重组人脑利钠肽治疗肺源性心脏病急性加重期患者的临床研究  

Clinical trial of recombinant human brain natriuretic peptide for injection in the treatment of patients with acute exacerbation of corpulmonale

作　　者：曹明嫄 吴允萍 宋晓霞 王莉 CAO Ming-yuan;WU Yun-ping;SONG Xiao-xia;WANG Li(Department of Respiratory,Lanzhou First People's Hospital,Lanzhou 730050,Gansu Province,China;Department of Pharmacy,Lanzhou First People's Hospital,Lanzhou 730050,Gansu Province,China;Department of Geriatrics,Lanzhou First People's Hospital,Lanzhou 730050,Gansu Province,China)

机构地区：[1]兰州市第一人民医院呼吸科,甘肃兰州730050 [2]兰州市第一人民医院药剂科,甘肃兰州730050 [3]兰州市第一人民医院老年病科,甘肃兰州730050

出　　处：《中国临床药理学杂志》2021年第13期1634-1637,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察注射用重组人脑利钠肽对肺源性心脏病急性加重期患者的治疗效果。方法将115例患者依据随机数字的方法分为对照组58例与试验组57例。对照组给予常规救治方案;试验组在对照组的基础上给予注射用重组人脑利钠肽:治疗前5 min,给予注射用重组人脑利钠肽1.5μg·kg^(-1),静脉滴注,之后以0.75×10^(-2)μg·kg^(-1)·min^(-1)连续静脉泵入。2组均治疗7 d。比较2组患者的内皮素-1(ET-1)、血管内皮生长因子(VEGF)、每搏输出量(SV)、左心室射血分数(LVEF)、心排出量(CO)、治疗效果和药物不良反应发生情况。结果治疗后,试验组和对照组的总有效率分别为100.00%(57例/57例)和89.66%(52例/58例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的ET-1分别为(50.03±6.21)和(58.25±7.26)ng·L^(-1),VEGF分别为(213.58±21.64)和(278.25±25.37)ng·L^(-1),SV分别为(60.21±4.52)和(55.17±4.92)mL,LVEF分别为(63.12±6.88)和(54.20±7.72)%,CO分别为(4.59±0.41)和(4.12±0.57)L·min^(-1),差异均有统计学意义(均P<0.05)。试验组和对照组在治疗过程中的药物不良反应发生率分别为3.51%(2例/57例)和5.17%(3例/58例),差异无统计学意义(P>0.05)。结论在常规治疗的基础上给予注射用重组人脑利钠肽,有利于改善肺源性心脏病急性加重期患者多个维度的病理指标,提升疗效,且安全性良好。Objective To observe the therapeutic effect of recombinant human brain natriuretic peptide for injection in the treatment of patients with acute exacerbation of corpulmonale.Methods The 115 patients were divided into control group of 58 cases and treatment group of 57 cases according to the random number method.Control group was given conventional treatment,treatment group was given recombinant human brain natriuretic peptide for injection on the basis of control group:5 min before treatment,recombinant human brain natriuretic peptide for injection 1.5μg·kg^(-1)was given intravenously,Afterwards,continuously pumped intravenously at 0.75×10^(-2)μg·kg^(-1)·min^(-1).The treatment of both groups was 7 d.The endothelin^(-1)(ET-1),vascular endothelial growth factor(VEGF),stroke volume(SV),left ventricular ejection fraction(LVEF),cardiac output(CO),treatmenteffect,and adverse drug reactions in two groups was compared.Results After treatment,the total effective rates of treatment group and control group were 100.00%(57 cases/57 cases)and 89.66%(52 cases/58 cases),with significant difference(P<0.05).After treatment,the ET-1 of treatment group and control group were(50.03±6.21)and(58.25±7.26)ng·L^(-1),VEGF were(213.58±21.64)and(278.25±25.37)ng·L^(-1),SV were(60.21±4.52)and(55.17±4.92)mL,LVEF were(63.12±6.88)%and(54.20±7.72)%,CO were(4.59±0.41)and(4.12±0.57)L·min^(-1),all with significant difference(all P<0.05).The incidence of adverse drug reactions in treatment group and control group during treatment were 3.51%(2 cases/57 cases)and 5.17%(3 cases/58 cases),without significant difference(P>0.05).Conclusion For patients with acute exacerbation of corpulmonale,recombinant human brain natriuretic peptide for injection was given on the basis of conventional comprehensive western medicine treatment method,which is beneficial to improve the pathological indicators of multiple dimensions,enhance the clinical effect,with good safty.

关 键 词：肺源性心脏病 肺动脉高血压 右心室功能 重组人脑利钠肽 心功能指标 

分 类 号：R972[医药卫生—药品]